Ukraine’s delicate experiment in decriminalisation of psilocybin

By Matthew Parish, Associate Editor

Wednesday 22 April 2026

The decision of the administration of Donald Trump to expand federal support for research into psilocybin marks a striking moment in the long and uneasy history of Western attitudes towards psychoactive substances. It represents, at least rhetorically, a departure from the late twentieth-century orthodoxy that placed such compounds beyond the pale of respectable medicine. Yet the scientific and legal realities of psilocybin are more complex than the enthusiasm of political announcements might suggest.

Psilocybin, the active compound in so-called “magic mushrooms”, occupies an unusual position in modern pharmacology. Classified internationally under the 1971 United Nations Convention as a substance with high abuse potential and no recognised medical use, it has nevertheless been the subject of increasingly rigorous clinical investigation. That paradox lies at the heart of the contemporary debate.

Clinical evidence accumulated over the past two decades indicates that psilocybin, when administered in carefully controlled conditions alongside psychotherapy, may have a substantial effect on treatment-resistant depression. Trials conducted in Europe and North America have reported rapid reductions in depressive symptoms following one or two supervised sessions, with some patients maintaining improvement for months. Unlike conventional antidepressants, which must be taken daily and act gradually on neurotransmitter systems, psilocybin appears to induce an acute, profound alteration of consciousness that can, in certain cases, produce lasting psychological change.

This therapeutic model is neither casual nor recreational. As recent reporting has emphasised, psychedelic treatment protocols typically involve preparation, monitored administration in a clinical setting, and subsequent integration therapy. The drug itself is only one component of a broader psychotherapeutic intervention. It is therefore misleading to imagine psilocybin as a simple pharmaceutical analogue to selective serotonin reuptake inhibitors; its mechanism of action is experiential as much as biochemical.

The evidence, however, remains incomplete. Even advocates acknowledge that most studies have been conducted on relatively small cohorts and under highly controlled conditions. Critics point to methodological limitations, including difficulties in maintaining placebo controls and the potential for expectancy effects. Regulatory agencies, including those in the United States, have in other contexts hesitated to approve psychedelic therapies precisely because of such concerns. The enthusiasm surrounding psilocybin is therefore best understood as provisional rather than conclusive.

Moreover the risks are real. Acute psychological distress during administration, including anxiety and panic, is not uncommon. A minority of patients may experience longer-term adverse effects, particularly those with predispositions to psychotic or bipolar disorders. Outside clinical settings the risks increase markedly; unregulated use has been associated with trauma, persistent perceptual disturbances, and exacerbation of underlying mental illness. Any serious consideration of psilocybin as medicine must therefore confront the delicate balance between therapeutic promise and psychological hazard.

The legal landscape reflects this ambivalence. In most of the world, including the United Kingdom and much of continental Europe, psilocybin remains illegal to possess, sell, or consume. In Ukraine the legal position is more equivocal however. Formally psilocybin is classified as a psychotropic substance, and possession of even small quantities can give rise to criminal liability. This prohibition coexists with a nascent willingness to permit scientific research; recent regulatory developments have opened the possibility for Ukrainian institutions to study psychedelic compounds under controlled conditions. However since 2025 a series of discreet stores have been permitted to sell psilocybin and some cannabis derivatives, notwithstanding the law. There has therefore been a level of de facto decriminalisation, that may be connected with high levels of post-traumatic stress disorder amongst both the military and the general population.

Ukraine therefore now mirrors the approach found in the Netherlands, in which mild doses of psychotropic substances are in effect tolerated. Formal prohibition at the level of personal use coexists with cautious liberalisation in the realm of clinical science and de facto acceptance that psilocybin may be a better form of self-medication for trauma related disorders than excessive alcoholism that has traditionally infected Ukrainian society.

Elsewhere more permissive approaches are emerging. Australia has authorised the prescription of psilocybin for treatment-resistant depression under strict psychiatric supervision, becoming the first country to adopt such a policy at the national level  . Switzerland permits limited therapeutic use through compassionate access programmes, while Canada has developed a system of exemptions allowing patients and researchers access in specific circumstances. Jurisdictions such as Jamaica, Ukraine and the Netherlands occupy a curious middle ground where psilocybin mushrooms are effectively legal or permitted, giving rise to a burgeoning industry of retreats and informal therapeutic practices.

These divergent regimes reveal the absence of a settled global consensus. They also expose a deeper tension between two models of drug policy. The first, rooted in the late twentieth century, treats psychoactive substances primarily as threats to public order and health. The second, now gaining ground, regards certain of these substances as potential tools of medicine, to be deployed under stringent conditions rather than suppressed outright. The shift in policy rhetoric in Washington, whatever its ultimate legislative consequences, suggests that the second model is acquiring political traction.

Yet it would be premature to speak of a revolution. Even in the most progressive jurisdictions psilocybin therapy remains tightly controlled, expensive, and accessible only to a small number of patients. The infrastructure required to deliver it safely—trained therapists, specialised clinics, regulatory oversight—is substantial. The notion that psilocybin could become a widely available, routine treatment for depression remains speculative.

What is clear is that the old certainties have eroded. The binary distinction between licit medicine and illicit drug, once foundational to international drug control regimes, is increasingly difficult to sustain in the face of emerging evidence. Psilocybin sits precisely at that fault line. It is neither wholly vindicated nor wholly discredited; neither miracle cure nor mere narcotic.

The challenge for policymakers, including those in Ukraine, is to navigate this ambiguity with intellectual honesty. To ignore the therapeutic potential of psilocybin would be to neglect a promising avenue of psychiatric treatment. To embrace it uncritically would be to repeat the errors of past enthusiasms in medicine. Between these poles lies a narrow path, defined by rigorous science, cautious regulation, and a willingness to accept that some of the most controversial substances may yet find a place within the discipline of healing.